care delivery
Let´s Start with the Definition The integrated management and delivery of quality and safe health services to people in need, along the continuum of disease prevention, diagnosis, treatment, disease-management, rehabilitation and palliative care services, through the different levels and sites of care within the health system, is the universally accepted to the definition of care delivery. (WHO) The goal of any health care delivery system should be to foster optimal health outcomes by providing cost-effective,
China is rapidly emerging as world’s fastest growing pharmaceutical industry. The market  is poised to reach $175B by 20221. Faster regulatory approvals and widening market access are some of the major drivers to this growth. China’s rapidly-moving health care industry and unique market characteristics has often required a pharmaceutical company to adopt a China specific development and launch strategy in isolation from other major markets. What are the key changes in market access and drug
A brief history Even though Alexander Fleming discovered the first antibiotic penicillin in 1928, it was introduced into the market as a commercial therapeutic for bacterial infection, only in 1940. It was Gerhard Domaghk who developed the first commercial antibacterial Prontosil, a sulfonamide, in 1930s. The introduction of penicillin marked the beginning of the ‘Golden Era’ for antibiotic discovery. For the next 40 years, many antibiotic classes e.g. β-lactams, aminoglycosides, tetracyclines, macrolides, glycopeptides and fluoroquinolones,
  The tediously long and risk-laden process of translating a discovery in biology to a marketable medical breakthrough starts with identifying a repertoire of molecules that will bring about the desired effect. What is it, really? Let´s start with the basics – the definition of phenotype itself. A phenotype is the physical expression of DNA. Phenotypes are caused by the interactions of the many different proteins created by DNA. A “phenotype” is any type of
Since 2015, the global injectable/parenteral drug delivery market is growing at a compounded rate of 11.8% and is forecasted to reach $640 million by 2021. It has the potential to soon eclipse oral delivery as the primary route of administration of pharmaceuticals, driven by the increased use of biological drugs.1 In 2017, Nine out of the top 10 products were biopharmaceutics while this number was just one, back in 2003.2 The biologics drug development has
The healthcare industry has been talking about adopting a ‘value-based care’ for some time now.1 Overall, the healthcare systems globally are going through a ‘volume-to-value’ shift with the key aim to improve patient outcomes, cost-effectively. Value-Based Contracting (VBC) and Real-World Evidence (RWE) are the underlying tools to achieve value-based care. Payers and providers increasingly want to understand the value of money they spend on high cost therapies. Value-based contracts link the contracted drug prices and